

B2 11 (Amended). A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

**Please add the following new claims:**

16. A compound according to claim 3 in which the B1 lysine residue is Phe.

B3 17. A compound according to claim 2 in which the insulin is human insulin.

18. A compound according to claim 3 in which the insulin is human insulin.

**IN THE ABSTRACT:**

**Please add the following Abstract of the Disclosure**

B4 A novel analogue of insulin has covalently conjugated thereto, preferably at the B1 residue, 3, 3', 5'-triiodothyroxine. The conjugate is believed to be hepatoselective, whilst it retains insulin receptor binding properties.